Asthma — Trials, FDA Actions & Pivotal Research
15 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Asthma.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Asthma trials
Recruiting trials by city
Cities where Asthma trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedAsthma: P-STEP Mobile App Usability Scores Increase Over 12 Weeks· May 1, 2026
- Results postedHFA-152a Propellant Shows Similar Mucociliary Clearance to HFA-134a· Apr 14, 2026
- Results postedAsthma: Mobile App Monitoring Improves Quality of Life and Reduces Healthcare…· Apr 8, 2026
- Results postedAsthma: School-Based Intervention Improves Daytime Symptoms, Stabilizes FEV1/FVC· Feb 9, 2026
- Results postedDepemokimab Phase 3 Extension Study Characterizes Long-Term Asthma Safety· Jan 15, 2026· drug: Depemokimab
- Results postedAsthma QIP Increases ICS-based Treatment Use by 12.79% in Phase 4 Trial· Jan 2, 2026
2025
- Results postedAsthma: E-cigarette Use Associated with Significant Reduction in Cigarettes…· Nov 18, 2025
- Results postedAsthma: CT Imaging Parameters Show Significant Link to Biologic Response· Nov 18, 2025
- Results postedAsthma: Technology-Assisted Intervention Shows Greater Adherence, Severity…· Sep 18, 2025
- Primary completionDepemokimab Phase 3 Trial for Severe Eosinophilic Asthma Completes Primary Study· Sep 14, 2025· drug: Depemokimab
- Results postedAsthma: Clinical Management Study Results Posted for 288 Patients· Aug 8, 2025
- Results postedAsthma: Home Air Quality Monitoring Feasibility Study Results Posted· Jul 29, 2025
- Results postedSevere Asthma: Body Reprogramming Feasibility Study Results Posted· Jul 11, 2025
- Results postedAsthma: US PRECISION Study Results Posted on Implementation Ease· Jul 8, 2025
- Primary completionDepemokimab Phase 3 Extension Study for Asthma Posts Long-Term Safety Data· May 19, 2025· drug: Depemokimab